TL/DR –
The National Taxpayers Union (NTU) has commended the Centers for Medicare and Medicaid Services (CMS) for its proposed changes to the 2027 Medicare Physician Fee Schedule, particularly its updates to the Medicare Prescription Drug Inflation Rebate Program. It praised the CMS for increasing transparency in the rebate program, thereby allowing for more accurate calculations of rebates, preventing duplicate discounts, and better supporting pharmaceutical research and development. However, the union criticized the Inflation Reduction Act’s price-setting provisions for certain drugs as having a “chilling effect” on pharmaceutical research and development, pointing out that 56 research programs and 26 drug developments have been discontinued since the Act’s passage.
The National Taxpayers Union (NTU), the oldest taxpayer advocacy organization in America, has expressed feedback on potential amendments to the 2027 Medicare Physician Fee Schedule and related Medicare policies proposed by the Centers for Medicare and Medicaid Services (CMS). Notably, the NTU voiced its support for the Medicare Prescription Drug Inflation Rebate Program’s proposed changes.
The NTU commends the CMS’s initiative to enhance the accuracy of Medicare’s inflation rebate calculations. Specifically, the CMS plans to oblige covered entities to submit claims data to a centralized federal database, facilitating the accurate identification of 340B-discounted units. This process will allow the CMS to administer Medicare inflation rebates in line with congressional intent.
The Fiscal Impact and Policy Implications of Medicare and Medicaid
The NTU offered insights into the fiscal implications of Medicare and Medicaid reimbursement policies and the need for strategic approaches that emphasize preventative diagnostics and treatments. This forward-thinking perspective could alleviate costly healthcare liabilities in the long run. The organization further emphasized the importance of robust prescription drug development, deployment, and payment policies, as these medications are scalable solutions that can prevent patients from requiring expensive healthcare settings.
According to NTU’s analysis, a policy environment that encourages access and innovation can reduce healthcare utilization in the long term by preventing costly medical procedures and hospitalizations. They expressed that it is crucial for the federal government, one of the world’s largest drug purchasers, to refrain from pricing and reimbursement practices that could inadvertently deter pharmaceutical research and development.
The Concerns about the Inflation Reduction Act
However, the NTU raised concerns that the Inflation Reduction Act’s price-setting provisions are already having a negative impact on pharmaceutical research and development (R&D). They cited data from the Incubate Coalition’s Life Sciences Investment Tracker, which reported that 56 research programs and 26 drug developments were discontinued following the passage of the Inflation Reduction Act.
The NTU warned that allowing Medicare inflation rebates to operate with limited safeguards could be harmful to taxpayers. Given projections that the share of federal noninterest outlays consumed by major health care programs will increase from 30% to 38% between 2026 and 2056, NTU argued that it is vital to avoid further disincentivizing pharmaceutical R&D.
Connecting the Dots: CMS Rules and Regulations
The NTU also highlighted the interconnectedness of CMS-1848-P with other proposed CMS regulations to implement the Inflation Reduction Act. They noted that changes to CMS procedures, even minor ones, need to be considered in the context of broader trends. They assert that policies lacking coordination can have nearly as detrimental an impact as those intended to expand government and harm taxpayers.
Lastly, the NTU stressed the importance of near-term wise decision-making regarding Medicare and Medicaid coverage for prescription drugs, devices, and diagnostic tools. They pointed to several studies and research papers demonstrating the value of early diagnostics, access to certain medications, and value-based care.
Call to Action
Through this rulemaking and other guidance and policy tools, the NTU implored CMS to address future fiscal challenges in government health programs by emphasizing early detection and prevention of costly treatments in the long run. They see this as a means to fortify availability of diagnostics, pharmaceuticals, and minimally invasive devices in the near term.
Signed by Alexander Ciccone, Policy and Government Affairs Manager, and Pete Sepp, President, the NTU expressed their commitment to service and thanked the CMS for their consideration.
—
Read More US Economic News